Preclinical CRO
APAC
Updated
Reviewed by Vidhi Upadhyay
APAC Real-World Evidence Services Market Industry Trends and Forecast to 2034: Segmented by (Source, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.48 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $540.8 Mn | — | — |
| 2025 (base) | $619.2 Mn | +$78.4 Mn | — |
| 2026 (forecast) | $709.0 Mn | +$89.8 Mn | +14.5% |
| 2027 (forecast) | $811.8 Mn | +$102.8 Mn | +31.1% |
| 2028 (forecast) | $929.5 Mn | +$117.7 Mn | +50.1% |
| 2029 (forecast) | $1.06 Bn | +$134.8 Mn | +71.9% |
| 2030 (forecast) | $1.22 Bn | +$154.3 Mn | +96.8% |
| 2031 (forecast) | $1.40 Bn | +$176.7 Mn | +125.3% |
| 2032 (forecast) | $1.60 Bn | +$202.3 Mn | +158% |
| 2033 (forecast) | $1.83 Bn | +$231.7 Mn | +195.4% |
| 2034 (forecast) | $2.09 Bn | +$265.2 Mn | +238.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $619.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.09 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 14.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Real-World Evidence Solutions |
| Segments | Source, application and end user (see all) |
| Key players | IQVIA, Optum, Inc., Flatiron Health, Aetion, TriNetX and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Real-world evidence services analyse health records, claims and registries to show how medicines work in everyday practice.
Key segments of the real-World Evidence Services market include source (EHR Data, Claims Data and Registries) and application (Drug Development, Market Access and Safety Monitoring).
Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the real-World Evidence Services market. Many companies now outsource work they used to do in-house.
Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the real-World Evidence Services market room to grow.
Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the real-World Evidence Services market.
The real-World Evidence Services market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
How care is paid for in some of these countries: Medicare and the PBS (Australia)[1], basic medical insurance (China)[2], the Hospital Authority (Hong Kong)[3], Ayushman Bharat PM-JAY (India)[4], public health insurance (Japan)[5], subsidised public care (Malaysia)[6], Pharmac (New Zealand)[7], PhilHealth (Philippines)[8], MediShield Life (Singapore)[9], the Universal Coverage Scheme (Thailand)[10], JKN (BPJS Kesehatan) (Indonesia)[11], out of pocket and Sehat Sahulat (Pakistan)[12], National Health Insurance (South Korea)[13] and social health insurance (Vietnam)[14].
[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[2] National Healthcare Security Administration. Checked 14 Nov 2026.
[3] Hospital Authority. Checked 14 Nov 2026.
[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[6] Ministry of Health Malaysia. Checked 14 Nov 2026.
[7] Pharmac. Checked 14 Nov 2026.
[8] PhilHealth. Checked 14 Nov 2026.
[9] CPF Board, MediShield Life. Checked 14 Nov 2026.
[10] National Health Security Office. Checked 14 Nov 2026.
[11] BPJS Kesehatan. Checked 19 Nov 2026.
[12] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.
[13] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.
[14] Vietnam Social Security. Checked 19 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how real-World Evidence Services services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Real-World Evidence Services right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Digital Health · APAC
Digital Health · APAC
Digital Health · APAC
Digital Health · APAC
Digital Health · APAC
Digital Health · APAC